Image

A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)

A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)

Recruiting
18-70 years
All
Phase N/A

Powered by AI

Overview

Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. However, there is a considerable lack of understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains clinically silent (or remains undetected) until the patients present with vascular occlusion. Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in individuals with Takayasu arteritis are needed. In this study, the investigators therefore to use different methods to identify new biomarkers for diagnosing or monitoring the disease activity in individuals with Takayasu arteritis. These biomarkers may provide valuable insights into the underlying biochemical processes and aid the understanding of the pathophysiology of this disease.

Eligibility

Retrospective

Inclusion Criteria:

        Subjects who met the American College of Rheumatology 1990 classification criteria for
        Takayasu arteritis:
          1. Age of onset ≤40 years,
          2. Claudication of upper or lower extremities,
          3. Decreased pulsation of 1 or both brachial arteries,
          4. Difference of ≥ 10 mmHg in systolic blood pressure between arms,
          5. Bruit over subclavian arteries or aorta,
          6. *Arteriographic evidence showing a branch of the aorta stenosis or occlusion.
        Meeting more than 3 of 6 criteria suggests the diagnosis of Takayasu arteritis.
        *Angiography in this study was replaced by vascular magnetic resonance angiography(MRA)or
        computed tomography angiography(CTA).
        Exclusion Criteria:
          1. Arteriographic lesions that could be entirely due to atherosclerosis,
          2. Suffer from other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus
             erythematosus, etc.) besides Takayasu arteritis,
          3. Cogan's syndrome,
          4. Behcet's disease,
          5. Subjects with any serious acute or chronic infection,
          6. Giant cell arteritis (large vessel vasculitis and at least 50 years old) or other
             infectious forms of large vessel vasculitis.
        Prospective
        Inclusion Criteria:
        Subjects with initial suspicion of having Takayasu arteritis or patients with Takayasu
        arteritis need assessment of disease activity were prospectively enrolled.
        Exclusion Criteria:
          1. Patients without image studies.
          2. Patients with confirmed other autoimmune diseases (eg, ANCA-associated vasculitis,
             systemic lupus erythematosus, etc.)

Study details
    Takayasu's Arteritis

NCT03372980

Beijing Institute of Heart, Lung and Blood Vessel Diseases

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.